|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:administeredBy
|
gptkb:prednisone
gptkb:dexamethasone
gptkb:melphalan
|
|
gptkbp:approvalYear
|
2003
|
|
gptkbp:ATCCode
|
L01XX32
|
|
gptkbp:brand
|
gptkb:Velcade
|
|
gptkbp:CASNumber
|
179324-69-7
|
|
gptkbp:chemicalFormula
|
C19H25BN4O4
|
|
gptkbp:contraindication
|
hypersensitivity to bortezomib
|
|
gptkbp:developer
|
gptkb:Takeda_Pharmaceutical_Company
gptkb:Millennium_Pharmaceuticals
|
|
gptkbp:eliminationHalfLife
|
40 hours
|
|
gptkbp:genericName
|
gptkb:bortezomib
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
gptkb:protease_inhibitor
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:proteinBinding
|
83%
|
|
gptkbp:routeOfAdministration
|
subcutaneous
intravenous
|
|
gptkbp:sideEffect
|
gptkb:peripheral_neuropathy
nausea
diarrhea
fatigue
thrombocytopenia
|
|
gptkbp:usedFor
|
gptkb:mantle_cell_lymphoma
multiple myeloma
|
|
gptkbp:bfsParent
|
gptkb:Takeda
gptkb:Takeda_Pharmaceutical_Company
gptkb:Takeda_Pharmaceutical
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Velcade
|